People In Health Care
Dr Marina Berbic
Genetic Pathologist and Deputy Director of Genetics
Douglass Hanly Moir Pathology
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
Australian Health Journal spoke to Dr Berbic about her career and being a genetic pathologist. She started as a junior doctor in obstetrics and gynaecology after completing a medical degree, though never thought about specialising in pathology. The more she learned about genetic pathology, the more intrigued she became, realising that this specialty aligned with both her strengths and interests.
Dr Berbic has always been interested in science, technology, and innovation. She first studied for a Bachelor of Medical Science degree, followed by a Master’s in Reproductive Health and Human Genetics and then a PhD in Reproductive Medicine. Dr Berbic has long-standing academic interests, both from a research and teaching perspective. She continues to be involved in medical education at the University of New South Wales in her role as an Adjunct Senior Lecturer.
After completing her specialist training and attaining fellowship of the Royal College of Pathologists of Australasia, she commenced her role as a genetic pathologist at Douglass Hanly Moir and later became the Deputy Director of Genetics department. Her role involves providing clinical governance and medical leadership that governs all aspects of medical testing in genetics.
In this interview, Dr Berbic talks about the exciting area of genetic pathology impacting multiple areas of medicine including paediatrics, obstetrics and gynaecology, cardiology, neurology, oncology, and other fields.
The results of genetic testing have a potential impact on the patient’s diagnosis, the decisions that couples may take when they’re making reproductive decisions, and also have predictive implications. The testing results may influence therapy, selection, or patient management and may have far ranging impact on the individual as well as their family.
You Might also like
-
New research papers show productivity gains and gaps
Commissioner Catherine De Fontenay talks about the Productivity Commission’s new approach to analysing health productivity, shifting the perspective from the unit measurement of individuals using the health system to the actual improvement of health. This has shown Australia’s health treatment productivity is improving, but identifies gaps in preventative health measures and duplication, where digital technology needs to be more effectively used.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.